NU1025

NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity[1][2][3].

Product Specifications

CAS Number

[90417-38-2]

UNSPSC

12352005

Hazard Statement

H302, H319

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nu1025.html

Concentration

10mM

Purity

98.50

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(N=C(C)NC2=O)C2=CC=C1

Molecular Formula

C9H8N2O2

Molecular Weight

176.17

Precautions

H302, H319

References & Citations

[1]Kaundal RK, et al. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci. 2006 Nov 10;79 (24) :2293-302.|[2]Bowman KJ, et al. Potentiation of anti-cancer agent cytotoxicity by the potent poly (ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer. 1998 Nov;78 (10) :1269-77.|[3]Delaney CA, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly (adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000 Jul;6 (7) :2860-7.